From vision to life-changing treatments
Cellicure's journey in cellular immunotherapy began with a clear mission: engineer NK cell treatments that work harder and safer for patients fighting cancer and inflammatory disease.
Transforming cancer care through innovative NK cell therapies
Cellicure exists to overcome unmet clinical needs in cancer, infectious diseases, and chronic inflammation. We're committed to developing treatments that work harder, last longer, and carry fewer risks than current options. That mission drives every decision we make.
Leaders in cellular immunotherapy research
Cellicure's team combines deep expertise in cell biology, immunology, and drug development to advance NK cell therapies that address critical unmet clinical needs.
Chief Scientific Officer
Dr. Michael Chen
Michael leads Cellicure's scientific strategy and oversees development of the Effic-NK™ expansion system. His expertise in NK cell biology and immunotherapy drives innovation in cell-based treatments.
Chief Executive Officer
Dr. Sarah Williams
Sarah brings strategic leadership and vision to Cellicure's mission of developing life-changing immunotherapies. She drives global partnerships and commercialization efforts for cancer and inflammatory disease treatments.
Head of Clinical Development
Dr. James Rodriguez
James oversees all clinical trial programs and regulatory strategy for Cellicure's NK cell therapies. His background in oncology and immunology ensures rigorous evaluation of treatment safety and efficacy.
Director of Manufacturing
Dr. David Patel
David leads production of Cellicure's high-yield NK cell treatments using the Effic-NK™ system. He ensures consistent quality and scalability of manufacturing processes in Germantown, Maryland.
How we make decisions at Cellicure
Our core values guide every research milestone, partnership, and innovation we pursue in cellular immunotherapy.
Patient impact first
We prioritize unmet clinical needs in cancer and chronic inflammatory diseases over market trends.
Science-driven approach
Every decision stems from rigorous data, validated mechanisms, and peer-reviewed evidence in immunology.
Simplicity in design
Our feeder-free Effic-NK™ system eliminates unnecessary complexity while maintaining superior cellular outcomes.
Functional innovation
Saftein™ technology delivers proven survival and renewal benefits without the toxicity of traditional cytokine approaches.
Transparent partnerships
We collaborate openly with clinical teams, sharing data and insights to advance collective understanding in immunotherapy.
Rapid advancement
Cellicure moves efficiently from concept to clinical application, accelerating solutions for patients waiting for treatment.
What Our Team Values Most
Cellicure team members share why they're committed to advancing cell-based immunotherapy and the impact of their work.
Working at Cellicure means being part of something bigger. Every day, I know our NK cell research could change outcomes for patients fighting cancer. That purpose drives everything we do.
Dr. Alexandra Chen
Senior Cell Biologist
The Effic-NK system is genuinely innovative. Unlike anything else in the field. Working on something this technically advanced, with a team that believes in it, makes the long hours feel meaningful.
Marcus Williams
Process Development Engineer
Cellicure trusts us to own our work. There's real autonomy here. We're not just executing someone else's vision. We're building the future of cell therapy together.
Dr. Priya Kapoor
Immunology Research Lead
The science here is rigorous, but the people make it special. Everyone is genuinely invested in solving real clinical problems. That's rare in biotech.
James Rodriguez
Quality Assurance Specialist
Build the future of immunotherapy with us
Cellicure is growing. If you're passionate about cell-based therapies and want to contribute to treatments that matter, we'd like to hear from you.